Sort
39,280 grants matching “leukemia”
Leukemia Specific Splice Isoforms as Neo-Antigens for T-Cell Immunotherapy
$500,397Paul Michael Armistead · Univ Of North Carolina Chapel Hill · R01 · FY2017 · CA
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
$500,364Guido Marcucci · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
$500,361Guido Marcucci · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia
$500,339Russell E Ware · Cincinnati Childrens Hosp Med Ctr · U01 · FY2025 · HL
Clinical treatment of advanced Merkel cell carcinoma
$500,321Isaac Brownell · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2024 · AR
New Gene Regulatory Proteins Regulating Erythroid Development
$500,265Harvey F Lodish · Boston Children'S Hospital · P01 · FY2011 · HL
Project 1: Development of an HTLV-1 mRNA vaccine
$500,231Amanda Robinson Panfil · Washington University · P01 · FY2025 · CA
A microfluidics-based paradigm for clinical lentivector gene transfer
$500,223Wilbur A Lam · Emory University · R01 · FY2020 · HL
A microfluidics-based paradigm for clinical lentivector gene transfer
$500,223Wilbur A Lam · Emory University · R01 · FY2021 · HL
TARGETING AML-STROMAL INTERACTIONS
$500,179John F Dipersio · Washington University · R01 · FY2015 · CA
INNATE IMMUNE THERAPIES IN B CELL MALIGNANCIES
$500,067John C Byrd · Ohio State University · P01 · FY2010 · CA
Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016)
$500,000Yang Liu · Oncoimmune, Inc. · R01 · FY2018 · FD
Targeting MCPyV to Overcome Immune Evasion in Merkel Cell Carcinoma
$500,000Paul Nghiem · University Of Washington · RC2 · FY2009 · CA
Identification of Altered Molecular Signature of Down Syndrome iPS Cells
$500,000John D Crispino · Northwestern University At Chicago · RC1 · FY2009 · HL
CyTOF Mass Cytometer
$500,000Garry P Nolan · Stanford University · S10 · FY2010 · RR
GENOMIC ANALYSIS OF ADOLESCENT AND YOUNG ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
$500,000Charles G. Mullighan · St. Jude Children'S Research Hospital · RC1 · FY2009 · CA
Epigenetic Markings in Developing and Diseased Prefrontal Neurons
$500,000Schahram Akbarian · Univ Of Massachusetts Med Sch Worcester · RC1 · FY2009 · MH
Reconstitution of Regulatory T Cells After Stem Cell Transplantation
$500,000Jerome Ritz · Dana-Farber Cancer Inst · R01 · FY2013 · CA
Canine models for characterization, diagnosis, and treatment of human cancers using comparative canine-human transcriptomics
$500,000Gregory Tawa · National Center For Advancing Translational Sciences · ZIA · FY2022 · TR
Nucleophosmin and ribosomal dysfunction in hematologic diseases
$500,000Pier Paolo Pandolfi · Beth Israel Deaconess Medical Center · RC1 · FY2010 · DK
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** CATTLE INFECTED WITH BOVINE LEUKEMIA VIRUS (BLV) HAVE COMPROMISED IMMUNE SYSTEMS WHICH ARE ASSOCIATED WITH A REDUCTION IN MILK PRODUCTION, SHORTENED LIFESPAN, AND PREDISPOSITION TO LYMPHOMA. OVER 21 NATIONS HAVE ERADICATED BLV BY ELIMINATING BLV ANTIBODY-POSITIVE ANIMALS. THE SERO-PREVALENCE IN U.S. DAIRY CATTLE IS ABOUT 50%, SO IT IS ECONOMICALLY AND PRACTICALLY IMPOSSIBLE TO CULL ALL INFECTED CATTLE TO ERADICATE THE DISEASE. IT IS PRIMARILY CATTLE WITH HIGH CONCENTRATIONS OF PROVIRUS (PVL) THAT ARE RESPONSIBLE FOR MOST TRANSMISSION OF BLV. THE PVL ASSAY PROVIDES A QUANTITATIVE MEASURE TO RANK THE MOST INFECTIOUS ANIMALS FOR SEGREGATION OR CULLING. OUR PILOT STUDY TO REMOVE HIGH PVL COWS WAS SUCCESSFUL IN GREATLY REDUCING BLV PREVALENCE AND INCIDENCE, BUT INCOMING INFECTED YOUNG STOCK HAVE PREVENTED ERADICATION IN SMALL HERDS. WE HYPOTHESIZE THAT BLV ERADICATION REQUIRES A COMPREHENSIVE APPROACH OF REMOVING ELISA-POSITIVE COWS AND PREVENTING INFECTED HEIFERS FROM ENTERING THE MILKING HERD. WE WILL ENROLL FIVE DAIRY HERDS (Μ =400) AND OBTAIN WHOLE-HERD BLV PREVALENCE VIA ELISA AND STRATIFY INFECTIOUSNESS VIA QPCR IN YEARS 1, 3, AND 5. PROVIRUS WILL BE MEASURED IN YOUNG STOCK TO PREVENT BLV-POSITIVE HEIFERS FROM ENTERING THE MILKING-HERD. REPEATED PVL TESTING OF THE HEIFERS WILL OCCUR AT WEANING, AFTER CONFIRMED PREGNANCY (~120 DAYS POST BREEDING), AND 60 DAYS IN MILK DURING LACTATION 1 THROUGH 3 TO DETERMINE BLV INCIDENCE. CONTROLLING BLV WILL MAKE THE U.S. DAIRY INDUSTRY MORE SUSTAINABLE AND PROFITABLE IN A GLOBAL MARKET WHERE MANY OTHER NATIONS HAVE MADE BLV CONTROL A PRIORITY.
$500,000Michigan State University · · FY2020 · National Institute of Food and Agriculture
Reconstitution of Regulatory T Cells After Stem Cell Transplantation
$500,000Jerome Ritz · Dana-Farber Cancer Inst · R01 · FY2017 · CA
Abramson Cancer Center Support Grant
$500,000Robert H Vonderheide · University Of Pennsylvania · P30 · FY2023 · CA
Development of Vaccine Strategies to prevent EBV+ Lymphoma in Patients with HIV
$500,000Robert Alan Baiocchi · Ohio State University · RC2 · FY2009 · CA
Molecular Mechanisms of MDS pathogenesis with aging
$500,000Stavroula Kousteni · Columbia University Health Sciences · R01 · FY2023 · AG